The poliovirion has been shown to exist in two basic antigenic forms, N (or D) and C (or H), that are not crossreactive. The N antigenic form is associated with mature infectious virus (1) . C antigenicity is observed in empty capsids isolated from infected cells, in mature virions that have been heated, modified, or degraded, and in virions that were bound to and eluted from membranes of suspectible cells (2) (3) (4) (5) (6) . By using nonsusceptible animals for immunization, neutralizing sera have been found to recognize the N antigenic state and have been obtained only when native virions are injected. These neutralizing sera bind to native virions but do not recognize C antigenic structures. Similarly, C-antigen-specific antibodies recognize heated or disrupted virions and procapsid structures but do not bind to native virions (7) (8) . Recently, a hybridoma cell line producing neutralizing monoclonal antibodies has been generated from mice that were injected with native virions (9) . In addition to binding to native virions, this antibody recognizes the 70S procapsid and the 14S assembly subunit, indicating that subunits of the virion previously thought to lack N antigenic sites do exhibit a neutralizing determinant. This raises the possibility that neutralizing antibodies could be induced by subunits of the virions and not only by the intact mature virion.
The determination of which of the poliovirus proteins can elicit a neutralizing response has proven elusive. The poliovirion contains four capsid proteins: VP1, VP2, VP3, and VP4. Neutralizing sera raised against mature virus and the monoclonal antibody do not recognize any of the capsid proteins selectively (9) . The conversion of N-reactive virions to C-reactive particles is typically accompanied with the loss of VP4, suggesting initially that VP4 might be the neutralizing determinant (10, 11) . Topological studies, however, indicate that VP4 is not located at the capsid surface (12) . Several attempts to raise a neutralizing antiserum by using single isolated capsid proteins have yielded equivocal results. In one study, none of the antisera raised against VP1, VP2, VP3, or VP4 were neutralizing (13) . In a more recent study, the antiserum from only one out of two rabbits injected with VP1 showed any neutralizing activity (14) . The antigenic specificity of the antiserum was not characterized further.
We present here data showing that all rats injected with isolated VP1 develop neutralizing antibodies to poliovirus. Rats injected with VP2 or VP3 generate antibodies that precipitate the cognate proteins and bind to virions but have no neutralizing ability. METHODS Production and Isolation of Poliovirus Capsid Proteins. Poliovirus type 1 (Mahoney) was isolated from infected HeLa cells. The capsid proteins VP1, VP2, and VP3 were isolated by NaDodSO4/polyacrylamide gel electrophoresis (15) . The virions were disrupted by boiling for 10 min in 1% NaDodSO4/ 5 mM EDTA and then subjected to electrophoresis through a preparative 13% NaDodSO4/polyacrylamide gel. The separated proteins were visualized as clear zones in the gel by precipitating the free NaDodSO4 in the acrylamide gel with 2.5 M KC1. The protein bands were cut out and electroeluted overnight and then dialyzed against 10 mM Tris-HCl, pH 7.5/1 mM EDTA. The concentrations of the eluted proteins were estimated in polyacrylamide gels by staining intensity relative to those of protein standards of known concentrations.
Immunizations. Male Lewis rats, 8 wk old (Charles River Breeding Laboratories), were injected intraperitoneally and intradermally with emulsions containing 100 ,ug of the isolated proteins. To equalize variability among the individual rats, each protein was injected into three rats. The emulsions were made by mixing equal volumes of the protein solution and complete Freund's adjuvant. After 3 wk, the initial injection was followed by three booster injections 2 wk apart. Each booster injection contained 100 ,ug ofprotein in a 50% emulsion with incomplete Freund's adjuvant. Animals were bled from the ocular sinus 8-10 days after each booster injection. Sera were heated to 65°C for 30 min before storage at -20°C. They were checked for the presence ofantibodies against the injected antigen using Ouchterlony double-diffusion plates.
Neutralizing Titers. 
7518
The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
Plaque Assays. The virus titers were determined using a cloned HeLa cell line S-3 that is carried in suspension but will also grow on plates. HeLa cells were plated at 2 x 106/60-mm plate in Dulbecco's modified medium/5% fetal calf serum. After 3 hr at 370C, the medium along with any floating cells was removed by aspiration and 200 1.d of the virus dilution (in phosphate-buffered saline) was placed on the monolayer. The plates were incubated for 30 min at 370C. The plates were then overlayed with 5 ml of 1% agarose in Dulbecco's modified medium/ 5% fetal calf serum and incubated at 370C for 36 hr (polio type 1, Mahoney) or for 54-72 hr (polio type 2, Lansing). All plaque assays were carried out in duplicate and plaques were visualized by staining with crystal violet.
[3S]Methionine-Labeled Virions. HeLa cells in medium lacking methionine were infected with poliovirus at a multiplicity of 10 pfu per cell. Cells were labeled with [3S]methionine (New England Nuclear; specific activity, 850 Ci/mmol; 1 mCi/ liter; 1 Ci = 3.7 x 1010 becquerels) 3.5 hr after infection and harvested 6 hr after infection. Cells were lysed in 1% Nonidet P40/10 mM Tris-HCl, pH 7.5/10 mM NaCl/1.5 mM MgCl2 and nuclei were removed by centrifugation., The virus was collected by centrifugation in a 50 Ti rotor for 1 hr at 45,000 rpm. The virus pellet was suspended in 10 mM Tris HCl, pH 7.5/ 1 mM EDTA/0.1 M NaCl/0.5% NaDodSO4 (TNE buffer/ 0.5% NaDodSO4) and banded in CsCl. The virus band was isolated, dialyzed against TNE buffer, and stored at -200C.
Immunoprecipitations. Immunoprecipitations were carried out in 10 mM Tris HCl, pH 7.5/0.15 M NaCl/1% deoxycholate/ 1% Triton X-100/0. 1% NaDodSO4 (Ripa buffer) in the presence of ovalbumin at 0.5 mg/ml. In some cases, just prior to incubation with the antisera, samples were denatured by boiling for 10 min in 1% NaDodSO4/5 mM EDTA and then centrifuged for 5 min in an Eppendorf centrifuge.
[3S]Methionine-labeled samples were incubated with a given amount of antiserum for 2 hr at room temperature and then for 30 min at 0°C with 10 times the serum volume of a 10% solution of formalin-fixed Staphylococcus aureus (Staph A) (New England Enzyme Center, Boston; Iggsorb). The Staph A was collected by centrifugation for 30 sec in an Eppendorf centrifuge, washed with three 1-ml portions of Ripa buffer/0.5 M NaCl and then with 1 ml of Ripa buffer/0. 15 M NaCl. Staph A-containing samples were boiled in the NaDodSO4 sample buffer for 10 min; the Staph A was removed by centrifugation and the supernatants were analyzed by electrophoresis through an 11% NaDodSO4/polyacrylamide gel (15) . The gels were fixed in 10% acetic acid/ 10% methanol, dried, and autoradiographed (Kodak, XAR film) at -700C.
RESULTS' Antisera Reactive with Individual Polypeptides. To study the antigenicity of poliovirus proteins VP1, VP2, and VP3, they were isolated and individually injected into rats, and serum samples were collected after each boost. The sera formed precipitin lines with the injected antigen in Ouchterlony doublediffusion assays (data not shown).
To test the specificity and selectivity of these antisera against denatured poliovirus capsid proteins, [3S]methionine-labeled poliovirions (Mahoney, type 1) were boiled in 1% NaDodSO4 and then immunoprecipitated with the sera. The precipitated samples were displayed by electrophoresis through an 11% polyacrylamide gel and detected by autoradiography (Fig. 1A) .
Antisera raised against VP1 specifically precipitated the VP1 released from dissociated virions (lanes 3 and 4) . Similarly, antisera raised against VP2 or VP3 precipitated only VP2 or VP3, respectively (lanes 6, 7, 9, and 10). None of the preimmune rat sera precipitated any specific virion proteins (lanes 2, 5, and 8). 
In every gel, several dilutions of [3-S]methionine-labeled vi-
rions at known protein concentrations and specific activity were displayed as protein standards. By comparing the intensities of the immunoprecipitated bands with those of the virion standards, an estimate was made ofthe number ofantigen molecules precipitated by a known volume of serum. After the second boost, 2 A.l of almost all of the rat sera precipitated a quantity of capsid protein equivalent to that found in 1010 particles. Because there are 60 molecules of each capsid protein in a virion, this represents almost 1012 molecules of antigen. Thus, each antiserum contains high titers of antibodies that are specific to only one capsid protein. The sera will be designated a-VP1, a-VP2, and a-VP3. To test whether the sera recognized any antigenic determinants on native virions, immunoprecipitations were done using [35s]methionine-labeled virions that had not been boiled in NaDodSO4 (Fig. 1B) . All of the antisera precipitated intact virions, although with various efficiencies. By comparing the intensities against virion standards, 2 1.l of a-VP1 or a-VP2 precipitated approximately 109 virion particles and 2 A.l of a-VP3 precipitated approximately 10 virions. Thus, only a small fraction of the antibodies produced against the denatured virion proteins recognized and bound to the proteins in their native state.
Neutralization Activity of Sera. Because the antisera recognized antigenic determinants on intact virions, they were tested for neutralizing activity. In one test, 200 pfu of poliovirus was incubated with 1:2 serial dilutions ofserum and the number of surviving pfu was measured with a plaque assay. The titers for neutralization of one-half of the input virions showed that only a-VPl contained any neutralizing activity (Table 1) . Even after a third boost, a-VP2 and a-VP3 showed no neutralization activity. In contrast, after each boost with VP1, the neutralizing titers of a-VPl increased such that, after the third boost with VP1, serum neutralizing titers had increased 10-fold over the titer obtained after the first boost. Although a-VP1, a-VP2, and a-VP3 immunoprecipitate VP1, VP2, and VP3 from poliovirus type 2 virions, respectively (data not shown), none of the rat antisera showed any neutralization activity against poliovirus type 2.
Because the serum titers were very low and neutralization activity was observed only with undiluted or very low dilutions of serum, a second neutralization protocol was used to test for the possibility of nonspecific inhibition. To this end, a high-titer stock of poliovirus was incubated with antiserum and the remaining virus was assayed after extensive dilution (Table 2) . No significant neutralization was apparent when 5 x 107 pfu of poliovirus was incubated with undiluted preimmune sera, a-VP2, or a-VP3. In contrast, virus decreased by approximately 1.5 log1o when incubated with a-VP1 serum. Thus, rats injected with a single capsid protein, VP1, produce sera that are capable of neutralizing poliovirions. Also significant is the observation that all rats that were injected with VP1 generated neutralizing antibodies.
Anti-Virion Antibodies. Because the neutralizing titers of a-VP1 appeared low, the neutralizing titers of sera from rats injected with whole virions (a-Vir) were measured as a standard ofcomparison. As expected, the a-Vir titers after the first boost were several orders of magnitude higher than the a-VP1 titers achieved after the third boost (Tables 1 and 2 ). To test the ability of a-Vir to bind to capsid proteins in their natural or denatured conformations, native and NaDodSO4-denatured virions were immunoprecipitated with a-Vir sera (Fig. 2) . Consistent with the high neutralizing titers observed, the antisera quantitatively precipitated native virions (Fig. 2,  lanes 1-6) . Thus, after the first boost, 2 dul of serum could immunoprecipitate approximately 1010 virion particles. None of the a-Vir sera, however, recognized any of the denatured proteins (Fig. 2, lanes 7-12) . Thus, antisera induced by virions appear to recognize different antigenic determinants than antisera raised against the individual proteins.
All antisera (a-VP1, a-VP2, a-VP3, and a-Vir) recognized and immunoprecipitated the capsid protein intracellular precursors from infected cell lysates in the absence of extensive denaturation (data not shown). The ability of poliovirus VP1 to elicit a neutralizing response might have been expected because the equivalent foot-andmouth disease virus (FMDV) and mengovirus polypeptides have previously been shown to elicit such a response (16) (17) (18) (19) (20) (21) . Like poliovirus, these are picornaviruses although of the aphthovirus and cardiovirus subgroups rather than the enterovirus subgroup (22) . Possibly all picornaviral VP1s would induce such a response.
Although a-VP2 and a-VP3 did not contain neutralizing antibodies, they did react with intact virions, implying that determinants of both VP2 and VP3 are on the viral surface. Previous radiolabeling and cross-linking studies had led to similar conclusions (12, 23) .
Although VP1 clearly contains a neutralizing determinant, it is probably not the same neutralizing determinant to which the a-Vir antibodies bind because such antiserum did not immunoprecipitate the isolated proteins. In addition, hybridoma cell lines have been isolated in other laboratories from mice injected with poliovirions that produce neutralizing antibodies. These antibodies do not recognize VP1 from disrupted virions (9) . Both lines of evidence suggest that the neutralizing determinants recognized by the a-Vir sera and a-VP1 are not identical.
The induction of neutralizing antibodies and the neutralization process are poorly understood phenomena, and the weakness of the neutralizing response elicited by isolated poliovirus VP1 could be due to many factors. Neutralizing antibodies must recognize the poliovirus proteins in their native conformation so that the NaDodSO4-denatured VP1 protein may be less efficient than nondenatured VP1 protein for generating antibodies that recognize the native conformation. Also prevents the virus from binding to the cellular receptor.
The demonstration that VP1 can stimulate a neutralizing response suggests that it may be possible to produce a poliovirus vaccine using only VP1 determinants. The neutralizing response seen thus far in rats is probably too low to be protective but, by appropriate manipulations, a more immunogenic form of VP1 might be found. One promising route to producing such a subunit vaccine would be the use of synthetic peptides representing the VP1 sequence (20) .
